# Bayer: Phase 1 study completed, 16 enrolled (Chronic Kidney Disease)

**Score:** 50/100

| Field | Value |
|---|---|
| Sponsor | Bayer |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Learn About How a New Nurandociguat Tablet is Absorbed and Processed in the Body Compared to an Old Tablet and How Food Affects the Way the New Tablet is Absorbed and Processed in the Body |
| NCT ID | NCT07722585 |
| Phase | Phase 1 |
| Status | completed |
| Conditions | Chronic Kidney Disease |
| Intervention types | drug |
| Target enrollment | 16 |
| Site countries | Germany |
| Posted | 2026-07-23 |
| Planned start | 2026-07-28 |
| Event | Completed |
| Event date | 2026-10-12 |
| Last update posted | 2026-10-19 |

## Why this score
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07722585). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.